-
公开(公告)号：US20220348634A1
公开(公告)日：2022-11-03
申请号：US17736917
申请日：2022-05-04
Applicant: Xencor, Inc.
Inventor： Gregory A. Lazar , Matthew J. Bernett
IPC: C07K14/705 , C07K19/00 , C07K16/46
Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
-
公开(公告)号：US11352412B2
公开(公告)日：2022-06-07
申请号：US16189917
申请日：2018-11-13
Applicant: Xencor, Inc.
Inventor： Gregory A. Lazar , Matthew J. Bernett
IPC: C07K14/705 , C07K19/00 , C07K16/46 , A61K38/00
Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
-
公开(公告)号：US11254727B2
公开(公告)日：2022-02-22
申请号：US17231848
申请日：2021-04-15
Applicant: Xencor, Inc.
Inventor： Gregory A. Lazar , Matthew J. Bernett
IPC: C07K14/705 , C07K16/46 , A61K38/00 , C07K19/00
Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
-
公开(公告)号：US20160264643A1
公开(公告)日：2016-09-15
申请号：US15159667
申请日：2016-05-19
Applicant: Xencor, Inc.
Inventor： Gregory A. Lazar , Matthew J. Bernett
IPC: C07K14/705
CPC classification number: C07K14/70521 , A61K38/00 , C07K16/46 , C07K19/00 , C07K2319/30 , C07K2319/31 , C07K2319/74
Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
-
公开(公告)号：US20190127437A1
公开(公告)日：2019-05-02
申请号：US16189917
申请日：2018-11-13
Applicant: Xencor, Inc.
Inventor： Gregory A. Lazar , Matthew J. Bernett
IPC: C07K14/705 , C07K16/46 , C07K19/00
Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
-
Patent Agency Ranking
公开(公告)号：US10155800B2
公开(公告)日：2018-12-18
申请号：US15159667
申请日：2016-05-19
Applicant: Xencor, Inc.
Inventor： Gregory A. Lazar , Matthew J. Bernett
IPC: C07K16/46 , C07K14/705 , C07K19/00 , A61K38/00
Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
-
公开(公告)号：US09371397B2
公开(公告)日：2016-06-21
申请号：US14142705
申请日：2013-12-27
Applicant: Xencor, Inc.
Inventor： Gregory A. Lazar , Matthew J. Bernett
IPC: C07K16/46 , C07K14/705 , C07K19/00
CPC classification number: C07K14/70521 , A61K38/00 , C07K16/46 , C07K19/00 , C07K2319/30 , C07K2319/31 , C07K2319/74
Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
Abstract translation: 本申请涉及靶向CD80和CD86的CTLA4-Ig免疫粘附素及其用途，特别是用于治疗目的。
-
公开(公告)号：US20210230250A1
公开(公告)日：2021-07-29
申请号：US17231848
申请日：2021-04-15
Applicant: Xencor, Inc.
Inventor： Gregory A. Lazar , Matthew J. Bernett
IPC: C07K14/705 , C07K19/00 , C07K16/46
Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
-
公开(公告)号：US09605061B2
公开(公告)日：2017-03-28
申请号：US14165487
申请日：2014-01-27
Applicant: XENCOR, INC.
Inventor： Gregory A. Lazar , Bassil I. Dahiyat , Matthew J. Bernett
CPC classification number: C07K16/22 , A61K2039/505 , C07H21/00 , C07K16/00 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/94
Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
-
公开(公告)号：US09475881B2
公开(公告)日：2016-10-25
申请号：US13747317
申请日：2013-01-22
Applicant: Xencor, Inc.
Inventor： Gregory A. Lazar , Sher Bahadur Karki , Gregory L. Moore
CPC classification number: C07K16/2887 , C07K16/2803 , C07K16/2878 , C07K2317/52 , C07K2317/524 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2317/92
Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.021 seconds)
